Transcription
Thomas Ramsay 0:06
So I'm Tom Ramsay, co founder and CO inventor and CEO for Imago System. The technology is software based novel image post processing technology. And it fills a need, where we've now reached the limit of what existing imaging modalities can accomplish. PET CT Xray, MR, and there's no new technology coming out, like a new CT or a new MR technology. And there's still data inside of all of the images that is fixed in today, a doctor simply can't see. So what we do is we take a mammogram, a CT, an x ray, and we can extract data from it, it's critical for doctors to be able to see that the otherwise would miss not because they're not great doctors, but the visual information is just not present. So for example, in dense breast mammograms, the FDA now has told all clinicians, they must tell a woman if she has dense breast tissue in her mammogram, and that it's a possibility that they may have cancer, and the doctors can't see it, we're removing that barrier. We're removing a similar barrier in angiography, where clinicians doing angiograms simply can't see all of the lesions that might be present in our technology vendors in real time, non invasively can transform that technology that exists in every imaging center in the world, into new additional images, almost like a new technology. But we see into the images that see into Dubai, we started out as a basis in our process, coming out of detecting, my brother and I who invented the technology, bomb detection, for carry on bags, satellite imaging, tuberculosis in Africa. And it wasn't until my cousin lost both of her daughters to metastatic breast cancer, that we said we need to get back into the medical and see how no other mother, no sister, no daughter is going to have an experience like that. As a result of this loss of the my cousin's two daughters, we said that there has to be a better way for medicine, to use the existing technologies that are there today, like mammography, and yet be able to reveal patterns in dense tissue so that no woman goes undiagnosed. Again, even if she has dense breast tissue. We're currently in our series B raising all of our images have been purchased. We're ready to go to FDA, we've had meetings with FDA with pre submission. And this seems to be a great opportunity to come and meet with investors and possible strategic partners. We're going to be licensing our technology not bringing to the market directly. So in that sense, an Intel model where we build the infrastructure to do the processing, and other companies strategics who already have a presence in the marketplace, can bring that to their customers. So it has been a great opportunity to be able to do so met really wonderful people here. And I'll simply say from LSI it's one of the most friendly environments of any conference. I've been to
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
